1. Home
  2. RTX vs NVO Comparison

RTX vs NVO Comparison

Compare RTX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RTX Corporation

RTX

RTX Corporation

HOLD

Current Price

$181.80

Market Cap

234.3B

Sector

Industrials

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$50.38

Market Cap

212.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RTX
NVO
Founded
1934
1923
Country
United States
Denmark
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.3B
212.7B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RTX
NVO
Price
$181.80
$50.38
Analyst Decision
Buy
Buy
Analyst Count
14
11
Target Price
$177.57
$54.25
AVG Volume (30 Days)
4.6M
18.5M
Earning Date
01-27-2026
02-04-2026
Dividend Yield
1.52%
2.45%
EPS Growth
38.64
10.06
EPS
4.87
3.67
Revenue
$85,988,000,000.00
$49,580,393,058.00
Revenue This Year
$8.82
$7.77
Revenue Next Year
$6.17
$1.86
P/E Ratio
$36.69
$13.69
Revenue Growth
8.79
16.64
52 Week Low
$112.27
$43.08
52 Week High
$181.31
$111.17

Technical Indicators

Market Signals
Indicator
RTX
NVO
Relative Strength Index (RSI) 67.28 55.77
Support Level $170.35 $46.08
Resistance Level $172.09 $50.75
Average True Range (ATR) 3.45 1.07
MACD 0.93 0.54
Stochastic Oscillator 99.48 92.93

Price Performance

Historical Comparison
RTX
NVO

About RTX RTX Corporation

RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: